Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: A case-control study
William L. Conte
Topics & Concepts
OcrelizumabMedicineMultiple sclerosisSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Antibody response2019-20 coronavirus outbreakVirologyImmunologyAntibodyInternal medicineRituximabDiseaseInfectious disease (medical specialty)OutbreakPeripheral Neuropathies and DisordersMultiple Sclerosis Research StudiesSARS-CoV-2 and COVID-19 Research